Syndax Pharmaceuticals, Inc. SNDX
18.20
0.23
1.28%
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow SNDX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
11.95 | 10.56 | 9.49 | 7.72 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.90) | (26.19) | (40.95) | (64.26) | |
P/B ratio |
11.55 | 28.16 | 49.53 | 128.84 | |
Price to Tangible BV |
11.55 | 28.16 | 49.53 | 128.84 | |
EV/Sales |
10.96 | 10.29 | 9.52 | 7.94 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.93) | (5.49) | (7.43) | (9.07) | |
EV/FCF |
(2.57) | (5.49) | (7.43) | (9.06) | |
Quick Ratio |
4.34 | 4.01 | 4.88 | 6.26 | |
Current Ratio |
4.64 | 4.40 | 5.47 | 6.77 | |
Net Debt/EBITDA |
1.84 | 1.09 | 0.50 | (0.84) | |
Debt/Assets |
62.33% | 64.92% | 72.77% | 83.58% | |
Debt/Equity |
2.98 | 5.32 | 8.26 | 38.95 | |
Asset Turnover |
0.23 | 0.27 | 0.39 | 0.39 | |
Operating CF/Net income |
1.16 | 1.02 | 1.18 | 0.61 | |
Capex/Depreciation |
0.06 | 0.04 | 0.00 | 0.08 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
122.69% | 114.84% | 90.72% | 93.47% | |
Selling, General and Administrative Expense of Revenue |
97.92% | 72.91% | 57.95% | 57.07% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
26.34% | 16.43% | 18.58% | 19.25% | |
Graham Net Nets |
0.07 | 0.03 | 0.02 | (0.01) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.46%) | (15.66%) | (11.94%) | (11.48%) | |
Free Cash Flow Yield |
(35.66%) | (17.74%) | (13.49%) | (11.35%) | |
Revenue per Share |
0.53 | 0.79 | 0.74 | 0.82 | |
Operating CF per Share |
(0.81) | (0.80) | (0.57) | (0.34) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.82) | (0.80) | (0.57) | (0.34) | |
Cash per Share |
5.24 | 4.78 | 4.09 | 6.23 | |
Shareholders Equity per Share |
1.33 | 0.75 | 0.47 | 0.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.33 | 0.75 | 0.47 | 0.17 | |
Free Cash Flow |
(70.67) | (69.54) | (50.34) | (30.31) | |
Working Capital |
415.64 | 407.97 | 385.00 | 575.36 | |
Capital Expenditures |
(0.13) | (0.06) | — | (0.04) | |
Net Current Asset Value |
93.47 | 63.01 | 40.13 | (13.51) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(132.36%) | (99.32%) | (65.79%) | (67.82%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
22.32 | 39.69 | 39.10 | 52.76 | |
Average Payables |
9.36 | 14.10 | 10.45 | 11.11 | |
Average Inventory |
— | 16.56 | 19.81 | 25.43 | |
Average Assets |
488.80 | 627.26 | 556.69 | 649.90 | |
Average Common Equity |
240.93 | 176.38 | 128.34 | 86.26 |
Columns are period end dates